Aflatoxin: A Synthesis of the Research in Health, Agriculture and Trade
Aflatoxin: A Synthesis of the Research in Health, Agriculture and Trade
Aflatoxin: A Synthesis of the Research in Health, Agriculture and Trade
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>in</strong> <strong>in</strong>fancy is <strong>the</strong> most effective approach to prevent liver cancer, particularly <strong>in</strong><br />
develop<strong>in</strong>g countries. 100 concurrent reduction <strong>of</strong> exposure to aflatox<strong>in</strong> B 1 may<br />
also prove an effective primary prevention measure. Vacc<strong>in</strong>es for prevention <strong>of</strong><br />
hepatitis c, however, are only just reach<strong>in</strong>g early-phase cl<strong>in</strong>ical trials. Anti-viral<br />
treatments aga<strong>in</strong>st hepatitis <strong>in</strong>fection may also <strong>in</strong>terrupt or delay <strong>the</strong> progression<br />
to hepatocellular carc<strong>in</strong>oma. 101<br />
A major challenge to <strong>in</strong>corporat<strong>in</strong>g <strong>the</strong> hepatitis B vacc<strong>in</strong>ation <strong>in</strong>to a national<br />
immunization program is how to ensure <strong>the</strong> availability <strong>of</strong> <strong>the</strong> vacc<strong>in</strong>e <strong>in</strong><br />
countries with prevalent cases <strong>of</strong> aflatox<strong>in</strong> poison<strong>in</strong>g. Key barriers to vacc<strong>in</strong>ation<br />
dissem<strong>in</strong>ation may <strong>in</strong>clude <strong>in</strong>sufficient fund<strong>in</strong>g, lack <strong>of</strong> access to technology, <strong>and</strong><br />
concerns about <strong>in</strong>tellectual property rights. Development <strong>of</strong> a vacc<strong>in</strong>e aga<strong>in</strong>st<br />
hepatitis c is more problematic, due to <strong>the</strong> genetic heterogeneity <strong>of</strong> <strong>the</strong> virus.<br />
however, with 24 percent <strong>of</strong> liver cancer <strong>in</strong> develop<strong>in</strong>g countries attributable to<br />
hepatitis c (approximately 93,000 cases per year), such a vacc<strong>in</strong>e would make<br />
a major contribution to cancer prevention. 102<br />
<strong>in</strong> nigeria, aflatox<strong>in</strong> <strong>and</strong> chronic hepatitis B <strong>in</strong>fection account for approximately<br />
8 to 27 percent <strong>and</strong> 59 to 62 percent <strong>of</strong> total liver cancers, respectively. <strong>of</strong> <strong>the</strong><br />
three aflatox<strong>in</strong> control strategies tested <strong>in</strong> nigeria (hepatitis B vacc<strong>in</strong>e, biocontrols,<br />
<strong>and</strong> a calcium adsorbent called novaSil clay), hepatitis B vacc<strong>in</strong>ation would<br />
reduce <strong>the</strong> greatest number <strong>of</strong> total liver cancer cases. out <strong>of</strong> 43,000 total liver<br />
cancer cases, it was calculated that <strong>the</strong> hepatitis B vacc<strong>in</strong>e, biocontrols, <strong>and</strong><br />
novaSil would reduce liver cancer by 49 percent, 5 to 19 percent, <strong>and</strong> 3 to 10<br />
percent, respectively, as shown <strong>in</strong> figure 10. 103<br />
Figure 10. Risk Reduction Estimates <strong>of</strong> Selected Control Interventions <strong>in</strong> Liver Cancer by Etiology<br />
items<br />
(per 100,00)<br />
<strong>in</strong>terventions<br />
26<br />
<strong>in</strong>cidence <strong>of</strong> liver cancer<br />
<strong>Aflatox<strong>in</strong></strong>-related HBv-<strong>in</strong>duced overall<br />
Basel<strong>in</strong>e risk 65.73 – 220.58 475.42 – 499.59 805.78<br />
Arr<br />
rrr<br />
nnt<br />
Vacc<strong>in</strong>e 50.76 – 170.39 450.44 – 475.81 395.05 – 424.47<br />
Biocontrol 37.17 – 151.47 31.27 – 127.41 36.98 – 151.82<br />
novaSil 26.29 – 88.23 22.12 – 74.22 26.30 – 88.23<br />
Vacc<strong>in</strong>e 0.77 0.95 0.49 – 0.53<br />
Biocontrol 0.57 – 0.69 0.06 – 0.27 0.05 – 0.19<br />
novaSil 0.40 0.04 – 0.16 0.03 – 0.11<br />
Vacc<strong>in</strong>e 587 – 1,970 210 – 222 236 – 253<br />
Biocontrol 660 – 2,690 785 – 3,198 659 – 2,704<br />
novaSil 1,133 – 3,803 1,347 – 4,521 1,133 – 3,803<br />
RRR = relative risk reduction; ARR = absolute risk reduction; NNT = number needed to treat; HBV = hepatitis B virus<br />
Awareness campaigns<br />
Dur<strong>in</strong>g <strong>the</strong> 2005 Kenya aflatox<strong>in</strong> outbreak, <strong>in</strong>dividuals received <strong>in</strong>formation<br />
on maize process<strong>in</strong>g <strong>and</strong> storage through an awareness campaign run by<br />
<strong>the</strong> food <strong>and</strong> Agricultural organization (fAo) <strong>of</strong> <strong>the</strong> United nations <strong>and</strong><br />
Kenya’s M<strong>in</strong>istry <strong>of</strong> health <strong>and</strong> M<strong>in</strong>istry <strong>of</strong> <strong>Agriculture</strong>. those <strong>in</strong>dividuals